Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Kasper Hjulmand Formation: 3 - 4 - 2 - 1 Manager: Lukas Kwasniok ...

The biotech giant is facing over 67,000 US lawsuits over allegations that its Roundup weedkiller causes cancer — a claim Bayer denies. Shares in Bayer rose over 9% during Tuesday morning trading in ...

Investing.com -- Bayer shares jumped on Monday after President Donald Trump’s administration urged the U.S. Supreme Court to take up the company’s bid to limit thousands of lawsuits alleging that ...

A file photo taken on September 1, 2019 shows Roundup weedkiller on sale that is the subject of thousands of lawsuits in the U.S. Bayer stock rose on Tuesday after the U.S. solicitor general backed ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The US government has backed a Supreme Court review of thousands of lawsuits alleging a key ingredient in Bayer ...

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals, a development that also helped a rival creating a competing drug. Bayer didn’t ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bayer reported positive results in a late-stage trial of an experimental stroke prevention medicine, sending ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

If you have ever wondered whether Bayer is really a bargain or just another risky pharma play, you are not alone. Let's dig into whether its current price matches up to its true worth. After a sharp ...

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Puhe BioPharma and Youngen Technology.